Skip Navigation

Nephrology Dialysis Transplantation 2006 21(Supplement 5):v9-v12; doi:10.1093/ndt/gfl476
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kessler, M.
Right arrow Articles by Schellekens, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kessler, M.
Right arrow Articles by Schellekens, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Immunogenicity of biopharmaceuticals

Michele Kessler1,, David Goldsmith2 and Huub Schellekens3

1Department of Nephrology-Dialysis-Transplantation, University Hospital of Nancy, France, 2Renal Medicine and Transplantation Department, Guy's Hospital, London, UK and 3Department of Innovation Studies, Utrecht University, Utrecht, The Netherlands

Correspondence and offprint requests to: Dr Michele Kessler, Service de Néphrologie, Hôpitaux de Brabois, CHU de Nancy, 54500 Vandoeuvre les Nancy, France. Email: m.kessler{at}chu-nancy.fr

The availability of biopharmaceuticals has been increasing over the past decade and as their patents expire, the emergence of biosimilar agents approaches. The primary issue of concern for the safety of these agents is the potential for immunogenicity. Both product- and host-related factors have documented impact on the immune response, but many factors are still unknown. Although in many cases the presence of antibodies may have little clinical consequence, the upsurge of pure red cell aplasia cases further increased concerns about potential clinical consequences of extensive use of biopharmaceuticals and biosimilars. Available laboratory measurement methods are insufficient to predict biological and clinical properties of biopharmaceuticals, or even to compare their bioequivalence. Comparison of results from different studies is complicated by the variability of assay measurements, presentation of data and lack of standardization.

Keywords: antigen; biopharmaceuticals; biosimilars; erythropoietin; immunogenicity; PRCA; risk factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
P. E. Johnson
Implications of biosimilars for the future
Am. J. Health Syst. Pharm., July 15, 2008; 65(14_Supplement_6): S16 - S22.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
J. Assuncao and J. Vinhas
Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
NDT Plus, June 10, 2008; (2008) sfn064v1.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. M. Dudzinski and A. S. Kesselheim
Scientific and Legal Viability of Follow-on Protein Drugs
N. Engl. J. Med., February 21, 2008; 358(8): 843 - 849.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.